SCHEMBL31247697

SCHEMBL31247697

CC(C)(C)OC(=O)N=S(C)(=O)c1cccnc1Nc1cc(N)ncn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNA2 P20248 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CDK5R1 Q15078 1/20 0.36
TYK2 P29597 3/20 0.34
JAK1 P23458 2/20 0.34
RET P07949 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 2/20 0.33
MAP4K4 O95819 1/20 0.33
AR P10275 1/20 0.33
NPSR1 Q6W5P4 2/20 0.33
NPC1 O15118 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31247372 0.79 CDK1 (0.46) CDK5CDK1CCNB1CCNA2CCNE1
SCHEMBL31300245 0.79 CDK1 (0.46) CDK5CDK1CCNB1CCNA2CCNE1
SCHEMBL31247721 0.79 TYK2 (0.34) TYK2JAK1RETMEN1KMT2A
SCHEMBL20129615 0.73 POLB (0.46) LMNAHTTRAB9AMETAP1
SCHEMBL2298689 0.71 MAP4K4 (0.47) CDK5CDK1CCNB1CCNA2CCNE1
SCHEMBL21989751 0.70 PABPC1 (0.45) ALDH1A1MEN1KMT2ALMNANPC1
SCHEMBL31247523 0.67 GRM5 (0.58) CDK5CDK1CCNB1CCNA2CCNE1
SCHEMBL20141065 0.66 EPHX2 (0.43) LMNA
SCHEMBL20141849 0.66 EPHX2 (0.43) LMNA
SCHEMBL20129610 0.66 EPHX2 (0.43) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 US disclosed
US-20240425484-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-26 US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE TYK2, FRK, DYRK2 CDK5 1766/4885CDK1 699/4885CCNB1 2851/4885
US-20240425484-A1 INHIBITORS OF TYK2 TYK2, LCK, JAK2 CDK5 977/4885CDK1 423/4885CCNB1 2570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.